BJMO - volume 13, issue 5, august 2019
M.J. Piccart-Gebhart MD
At ASCO 2019, many presentations featured recent progress in the breast cancer field. A lot of attention went to biomarkers but also the treatment of triple negative breast cancer, luminal disease, HER2 positive disease as well as agnostic breast cancers subtypes were discussed.
Read moreBJMO - volume 13, issue 5, august 2019
P. Specenier MD, PhD
ASCO 2019 hosted several important presentations on Squamous Cell Carcinoma of the Head and Neck (HNSCC). Data on early stage and locally advanced HNSCC as well as recurrent/metastatic HNSCC were discussed.
Read moreBJMO - volume 13, issue 5, august 2019
J. Vansteenkiste MD, PhD, E. Wauters MD, PhD
In this article, the ten key messages with respect to thoracic oncology presented at ASCO 2019, are summarized.
Read moreBJMO - volume 13, issue 5, august 2019
M. Peeters MD, PhD, H. Prenen MD, PhD
At ASCO 2019, several clinical trials regarding upper and lower gastro-intestinal tumors were presented.
Read moreBJMO - volume 13, issue 5, august 2019
Tom Feys MBA, MSc, P. Vuylsteke MD
The highlights in gynecologic cancers from ASCO 2019 include data on the outcome of chemotherapy or PARP inhibitors as monotherapy or combination therapy in (elderly) patients with ovarian cancer, as well as results of immune checkpoint blockade in patients with advanced or recurrent endometrial cancer with or without a mismatch repair deficiency. Novel findings in (early-stage) cervical cancer include the efficacy and safety of neoadjuvant chemotherapy followed by surgery vs. chemoradiation, and of minimally invasive hysterectomy compared to open radical hysterectomy.
Read moreBJMO - volume 13, issue 4, june 2019
W. Lybaert MD, H. Prenen MD, PhD, A. Demols MD, PhD, I. Dero MD
At the background of the Golden Gate Bridge with a view on the Pacific Ocean, the annual Gastrointestinal Cancers Symposium was held from 17–19 January 2019 in the Moscone Congress Center in San Francisco, California. The meeting further underlined the invasion of immunotherapy in the treatment landscape of gastrointestinal tumours, both in the upper and lower digestive tract. In addition to immunotherapy, lots of efforts were made in the molecular profiling of gastrointestinal cancers in every possible tumour location, which will hopefully fuel more biomarker-driven medicine in this setting in the near future. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2019;13(4):142–149)
Read moreBJMO - volume 13, issue 3, may 2019
Tom Feys MBA, MSc, J. Beekwilder PhD
The 2019 annual American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium was held from February 14-16 in San Francisco. The Belgian Multidisciplinary Meeting on Urological Cancers (BMUC) organised a post-ASCO GU regional tour during which the highlights of the 2019 ASCO GU meeting were discussed. This tour featured four different meetings in four locations in Belgium: Namur, Ghent, Nivelles and Paal. This summary will specifically report on the meeting held in Ghent during which prof. dr Piet Ost (Ghent University Hospital) and prof. dr Sylvie Rottey (Ghent University Hospital) gave a summary of the most important advances in the treatment of prostate, bladder and renal cancer.
(BELG J MED ONCOL 2019;13(3):109–114)
Read more
Top
